In addition to drug screening, in silico methods can help identify new upstream regulators of mitochondrial dysfunction in PD, as was shown in the identification of ATF4, which is a regulator of transcriptional changes identified in Pink1 and Parkin mutants [57]. This evidence concerns the gene PRKN and Parkinson disease.